Atea Pharmaceuticals AVIR 深 沪
已收盘 08-01 16:00:00 美东时间
3.47
-0.170
-4.67%
华盛通- 最 高3.685
- 今 开3.59
- 成交量 31.37万股
- 最 低 3.46
- 昨 收 3.64
- 总市值 2.97亿
- 52周最高 4.145
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 2.455
- 委 比 84.61%
- 总股本 8557.95万
- 历史最高 94.174
- 量 比 0.93
- 振 幅 6.18%
- 历史最低 2.455
- 每 手 1
- 风险率 0.38%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Atea Pharmaceuticals to Host Second Quarter 2025 Financial Results and Business Update Conference Call on August 7, 2025
Atea Pharmaceuticals will host a live conference call and webcast on August 7, 2025, at 4:30 p.m. ET to discuss Q2 2025 financial results and provide a business update. Participants can join via telephone using conference ID 10201618 or access the webcast at ir.ateapharma.com. Atea specializes in developing oral antiviral therapies for serious viral diseases, particularly targeting ssRNA viruses. Forward-looking statements in the release reflect ...
07-31 11:00
Atea Begins Global Late-Stage Trial of Oral Hepatitis C Drug Combo Aimed at Easier, Faster Cure
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced
06-24 19:07
Atea Pharmaceuticals Announces Continued Advancement of Global Phase 3 HCV Program with Dosing of First Patient in C-FORWARD Outside North America
Atea Pharmaceuticals has initiated the Phase 3 C-FORWARD trial to evaluate a new HCV treatment regimen of bemnifosbuvir and ruzasvir. This trial follows the C-BEYOND trial, both aiming to compare the regimen with the existing sofosbuvir and velpatasvir combination. The new regimen offers a shorter treatment duration, reduced risk of drug interactions, and convenience with no food restrictions. Globally, HCV affects 50 million people, including up...
06-24 11:00
Atea Pharma Presents Results From Full Cohort Of Patients Enrolled In Phase 2 Study Evaluating Once-daily Combination Of BEM And RZR For Treatment Of Hepatitis C Virus
Full Results from Phase 2 Study Confirmed 98% Sustained Virologic Response at 12 Weeks Post-Treatment (SVR12) After Short 8-Week Treatment Duration for RegimenResults from Phase 1 Study Showed Low Risk for Drug-Drug
05-07 19:04
“HPV男女共防计划”北半马主题活动在京举办
澎湃新闻记者 劳理 4月18日，由新华网发起、默沙东（默沙东是美国新泽西州罗威市默克公司的公司商号）支持的“畅跑马拉松，防护你我他”——“HPV男女共防计划...
04-21 22:07
Atea Pharmaceuticals Announces Board Changes and Share Buyback
An announcement from Atea Pharmaceuticals ( ($AVIR) ) is now available. On Apri...
04-17 20:27
Atea Pharmaceuticals announces share repurchase program
Atea Pharmaceuticals (NASDAQ:AVIR) announced on Thursday the appointment of Howard H. Berman to its board. Atea also announced that its board has authorized, and will promptly begin executing upon, t...
04-17 20:07
美股大行评级 | 潜在涨幅223.78%！内克塔治疗获杰富瑞升目标价至2美元，上调至"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1117736711687032832.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 杰富瑞：上调内克塔治疗(NKTR)评级至"买入"，目标价从1美元升至2美元</p> <p>• Roth MKM：维持Lovesac Co.(LOVE)"买入"评级，目标价从22美元升至28美元</p> <p>• Macq
04-14 07:05
Morgan Stanley Maintains Equal-Weight on Atea Pharmaceuticals, Lowers Price Target to $6
Morgan Stanley analyst Matthew Harrison maintains Atea Pharmaceuticals (NASDAQ:AVIR) with a Equal-Weight and lowers the price target from $6.2 to $6.
04-11 23:28
Atea Pharmaceuticals cuts workforce by ~25% in Q1
Atea Pharmaceuticals (NASDAQ:AVIR) announced on Wednesday an about 25% reduction in the workforce during the first quarter. The layoffs are expected to result in cost savings of ~$15M through 2027. Sh...
03-27 02:09
